Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · September 03, 2024

Molecularly Guided Therapy vs Chemotherapy After Disease Control in Unfavourable Cancer of Unknown Primary

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
Lancet 2024 Aug 10;404(10452)527-539, A Krämer, T Bochtler, C Pauli, KK Shiu, N Cook, JJ de Menezes, RA Pazo-Cid, F Losa, DG Robbrecht, J Tomášek, C Arslan, M Özgüroğlu, M Stahl, F Bigot, SY Kim, Y Naito, A Italiano, N Chalabi, G Durán-Pacheco, C Michaud, J Scarato, M Thomas, JS Ross, H Moch, L Mileshkin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading